Clinical Trials Debate Continues: Asian American women want their fair share of clinical trials--but what is fair?

IMPROVEMENT ON THE WAY: NAWHO President Mary Chung says that better education within the Asian American community will incease participation of Asian American women in clinical trials. Asian Americans comprise approximately 4 percent of the U.S. population, and they now account for 4 percent of the women enrolled in U.S. National Institutes of Health-sponsored clinical trials. This satisfies the spirit of the NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Resea

Written byMyrna Watanabe
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

IMPROVEMENT ON THE WAY: NAWHO President Mary Chung says that better education within the Asian American community will incease participation of Asian American women in clinical trials. Asian Americans comprise approximately 4 percent of the U.S. population, and they now account for 4 percent of the women enrolled in U.S. National Institutes of Health-sponsored clinical trials. This satisfies the spirit of the NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research, promulgated in 1994 in response to Congress's NIH Revitalization Act of 1993. The will of Congress was to ensure that women and minorities were included proportionally in NIH-sponsored clinical trials (M. Watanabe, The Scientist, 9[5]:14, March 6, 1995). But health activists in the Asian American communities are not satisfied with the 4 percent representation in clinical trials. And, as pointed out by oncologist Otis Brawley, director of the Office of Special Populations of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies